Key result
Malignant brain tumors induce a hypercoagulable state, and the perceived risk of perioperative intracranial bleeding with antithrombotic prophylaxis appears not to be justified by available evidence.
Why the study?
Does antithrombotic prophylaxis and therapy safely prevent venous thromboembolism in patients with primary and secondary cerebral tumors?
Population
Patients receiving treatment for primary and secondary cerebral tumors
Design
Review
Authors
Loading...
Challenges historical avoidance of antithrombotic prophylaxis in brain tumors; leaves open need for RCTs to confirm safety.
Does antithrombotic prophylaxis and therapy safely prevent venous thromboembolism in patients with primary and secondary cerebral tumors?
Antithrombotic prophylaxis appears safe and potentially superior to caval filters for preventing venous thromboembolism in brain tumor patients, despite historical concerns about intracranial bleeding.
Walsh et al. (2001) conducted a review in Primary and secondary cerebral tumors. Antithrombotic prophylaxis and therapy was evaluated. Malignant brain tumors induce a hypercoagulable state, and the perceived risk of perioperative intracranial bleeding with antithrombotic prophylaxis appears not to be justified by available evidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: